ArticleDiabetes care2015
Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists.
Article in Diabetes care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04841096 (Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure
Who cites it
22 citing papers in PubMed.
- Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM).Diabetes, obesity & metabolism · 2018Trial
- Trial
- Income and Severe Hypoglycemia in Type 2 Diabetes.JAMA network open · 2025Article
- Terminal trajectory of HbAFrontiers in endocrinology · 2024Article
- Artificial intelligence applied in cardiovascular disease: a bibliometric and visual analysis.Frontiers in cardiovascular medicine · 2024Article
- Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study.Journal of endocrinological investigation · 2023Article
- Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care.Cardiovascular diabetology · 2022Observational
- Considering Insulin Secretory Capacity as Measured by a Fasting C-Peptide/Glucose Ratio in Selecting Glucose-Lowering Medications.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2022Article
- Trends in HbAPharmacoepidemiology and drug safety · 2021Article
- Mobile Clinical Decision Support System for the Management of Diabetic Patients With Kidney Complications in UK Primary Care Settings: Mixed Methods Feasibility Study.JMIR diabetes · 2020Article
- Article
- Article
- Clinical inertia in type 2 diabetes management in a middle-income country: A retrospective cohort study.PloS one · 2020Article
- National physician survey on glycemic goals and medical decision making for patients with type 2 diabetes.Medicine · 2019Article
- Association between BMI and risk of severe hypoglycaemia in type 2 diabetes.Diabetes & metabolism · 2019Article
- Association of Hemoglobin ADiabetes care · 2018Observational
- A Proposal for an Out-of-Range Glycemic Population Health Safety Measure for Older Adults With Diabetes.Diabetes care · 2017Article
- Hemoglobin ADiabetes care · 2017Article
- Clinical characteristics and outcomes of the oldest old people with type 2 diabetes - perspective from a tertiary diabetes center in Thailand.BMC endocrine disorders · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveObservations over the past few years have demonstrated the need to adjust glycemic targets based on parameters pertaining to individual patient characteristics and comorbidities. However, the weight and value given to each parameter will clearly vary depending on the experience of the provider, the characteristics of the patient, and the specific clinical situation. RESEARCH DESIGN AND
methodsTo determine if there is current consensus on a global level with regard to identifying these parameters and their relative importance, we conducted a survey among 244 key worldwide opinion-leading diabetologists. Initially, the physicians were to rank the factors they take into consideration when setting their patients' glycemic target according to their relative importance. Subsequently, six clinical vignettes were presented, and the experts were requested to suggest an appropriate glycemic target. The survey results were used to formulate an algorithm according to which an estimate of the patient's glycemic target based on individualized parameters can be computed. Three additional clinical cases were submitted to a new set of experts for validation of the algorithm.
resultsA total of 151 (61.9%) experts responded to the survey. The parameters "life expectancy" and "risk of hypoglycemia from treatment" were considered to be the most important. "Resources" and "disease duration" ranked the lowest. An algorithm was constructed based on survey results. It was validated by presenting three new cases to 57 leading diabetologists who suggested glycemic targets that were similar to those calculated by the algorithm.
conclusionsThe resultant suggested algorithm is an additional decision-making tool offered to the clinician to supplement clinical decision making when considering a glycemic target for the individual patient with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.